Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients.

Molecular cancer therapeutics - 1 May 2005

Martínez Nerea, Sánchez-Beato Margarita, Carnero Amancio, Moneo Victoria, Tercero Juan C, Fernández Isabel, Navarrete Mercedes, Jimeno José, Piris Miguel A

Abstract excerpt

Ecteinascidin 743 (ET-743; Yondelis, Trabectedin) is a marine anticancer agent that induces long-lasting objective remissions and tumor control in a subset of patients with pretreated/resistant soft-tissue sarcoma. Drug-induced tumor control is achievable in 22% of such patients, but there is no clear indication of the molecular features correlated with clinical sensitivity/resistance to ET-743. Nine low-passage,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to Cell Cycle

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dioxoles

Share to Drug Resistance, Neoplasm

Share to Isoquinolines

Share to Oligonucleotide Array Sequence Analysis

Share to Sarcoma

Share to Tumor Cells, Cultured

Source

Identifiers

PMID: 15897246
DOI: 10.1158/1535-7163.MCT-04-0316

Genes

ATF3
BRCA1
JUNB
RAD17

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients.PMID 15897246Read ↗

Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53.Semantic proximity Read ↗

Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.Semantic proximity Read ↗

Ezrin Inhibition Up-regulates Stress Response Gene ExpressionSemantic proximity Read ↗

Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric studySemantic proximity Read ↗

ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma.Semantic proximity Read ↗

Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survival.Semantic proximity Read ↗

Von Hippel-Lindau–Coupled and Transcription-Coupled Nucleotide Excision Repair–Dependent Degradation of RNA Polymerase II in Response to TrabectedinSemantic proximity Read ↗

Aven‐mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcomaSemantic proximity Read ↗

Cisplatin Resistance in Osteosarcoma: In vitro Validation of Candidate DNA Repair-Related Therapeutic Targets and Drugs for Tailored TreatmentsSemantic proximity Read ↗

Gene Expression Profiles Classify Human Osteosarcoma Xenografts According to Sensitivity to Doxorubicin, Cisplatin, and IfosfamideSemantic proximity Read ↗

Associations of chemo- and radio-resistant phenotypes with the gap junction, adhesion and extracellular matrix in a three-dimensional culture model of soft sarcoma.Semantic proximity Read ↗

Characterization and Drug Resistance Patterns of Ewing's Sarcoma Family Tumor Cell LinesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.